|Ms. Emma Walmsley||CEO & Director||3.92M||428.24k||1970|
|Mr. Simon P. Dingemans||CFO & Exec. Director||2.83M||648.98k||1964|
|Mr. Jack Bailey||Pres of US Pharmaceuticals||N/A||N/A||N/A|
|Ms. Karenann K. Terrell||Chief Digital & Technology Officer||N/A||N/A||1961|
|Dr. Hal V. Barron||Chief Scientific Officer, Pres of R&D and Director||N/A||N/A||1963|
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories primarily under the Otrivin, Panadol, Fenistil, Lamisil, Breathe Right, Stiefel, Excedrin, Physiogel, Polident, parodontax, Poligrip, Sensodyne, Theraflu, and Voltaren brand names. The company offers its consumer healthcare products in the form of tablets, caplets, infant syrup drops, syrups, topical gels, nasal sprays, effervescents, lozenges, gum and trans-dermal patches, malted drinks and foods, and topical creams and non-medicated patches, as well as toothpastes, toothbrushes, mouth rinses, medicated mouthwashes, gels and sprays, denture adhesives, and denture cleansers. It has a discovery collaboration agreement with Kymera Therapeutics LLC; a collaboration agreement with InSysBio LLC to develop quantitative systems pharmacology model of asthma; and a strategic collaboration with NeuroMetrix, Inc. to develop and market Quell technology. GlaxoSmithKline plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.
GlaxoSmithKline plc’s ISS Governance QualityScore as of November 1, 2018 is 9. The pillar scores are Audit: 10; Board: 2; Shareholder Rights: 1; Compensation: 8.